Table 2.
Groups | ND/ND | HF/ND | ND/HS | HF/HS | HF/HS+M |
---|---|---|---|---|---|
l-citrulline | 57.2 ± 1.1 | 49.1 ± 1.6 | 95.2 ± 2.8 a,b | 85.8 ± 1.8 a,b | 45 ± 1.6 c,d |
l-arginine | 288.3 ± 6.7 | 208 ± 5.8 a | 285.2 ± 3.0 b | 287.4 ± 5.8 b | 221.9 ± 2.7 a,c,d |
ADMA | 1.01 ± 0.03 | 1.05 ± 0.05 | 2.34 ± 0.04 a,b | 2.3 ± 0.09 a,b | 1.48 ± 0.09 c,d |
SDMA | 0.61 ± 0.01 | 0.59 ± 0.01 | 3.12 ± 0.12 a,b | 2.84 ± 0.08 a,b | 0.55 ± 0.04 c,d |
l-arginine-to-ADMA ratio | 226.2 ± 3.0 | 201.9 ± 11.3 | 123.1 ± 2.6 a,b | 128.9 ± 3.8 a,b | 191 ± 24 c,d |
ADMA, asymmetric dimethylarginine; SDMA, symmetric dimethylarginine; HF/ND, maternal high fructose intake; ND/HS, post-weaning high salt intake; HF/HS, maternal high fructose intake plus post-weaning high salt intake; HF/HS+M, maternal high fructose intake plus post-weaning high salt intake and treated with melatonin; a p < 0.05 vs. ND/ND; b p < 0.05 vs. HF/ND; c p < 0.05 vs. ND/HS; d p < 0.05 vs. HF/HS.